SENSEX NIFTY

Drugs

Mar 04, 2015 at 15:10 | Source: Moneycontrol.com
Shares of Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company (SPARC) rallied 9-10 percent intraday on Wednesday to hit record highs of Rs 1,035 and Rs 448.80, respectively. SPARC, the subsidiary of pharma major, has received approval from US Food and Drug Administration (USFDA) for antiepileptic drug.
Mar 04, 2015 at 15:02 | Source: Moneycontrol.com
Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the United States Patent and Trademarks Office (USPTO) granted a US process patent for its novel stem-cell based drug Stempeucel.
Mar 04, 2015 at 12:00 | Source: Moneycontrol.com
Sun Pharma topped the buying list on Sensex, up 6 percent. Even its subsidiary Sun Pharma Advanced Research Company gained 6 percent on getting US FDA nod for Elepsia XR extended release tablets, an anti-epileptic drug. SPARC says product will be manufactured by Sun Pharma at Halol unit.
Mar 04, 2015 at 10:13 | Source: Moneycontrol.com
Sun Pharma Advanced Research Company today announced that the USFDA has approved its New Drug Application (NDA) for ELEPSIA XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg). ELEPSIA XRTM is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.
Mar 03, 2015 at 16:49 | Source: PTI
The DC Federal Court in the US has upheld the decision of the USFDA for rescinding tentative approvals given to it for generic digestive disorder drug Nexium and antiviral Valcyte.
Mar 02, 2015 at 20:15 | Source: PTI
As on December 31, 2014, the company had a total of 781 filings for formulations of which 333 have been approved in various regions globally.
Mar 02, 2015 at 17:10 | Source: Moneycontrol.com
Concord Drugs has reported a sales total income from operations of Rs 10.11 crore and a net profit of Rs 0.13 crore for the quarter ended Dec '14
Mar 02, 2015 at 16:11 | Source: Moneycontrol.com
Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, the generic version of Singulair Chewable Tablets (of Merck), which is used for the treatment of asthma and to relieve symptoms of seasonal allergies.
Mar 02, 2015 at 13:35 | Source: Reuters
Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.
Mar 02, 2015 at 10:48 | Source: Moneycontrol.com
Dr Datsons Labs and AL-MUGDH PHARMA of Yemen have singed a licensing, distribution and supply deal, under which the distribution company will market Anti-Malarial drugs.
Messages on Drugs »

maximindia

Platinum Member

684 Followers

Ranbaxy Labs  

If one notice everyday USA approving many indian co`s formulation in many blockbuster drugs and naturally RBaxy and SUN is in t top of lists.Reasoning is not far to see that USA want Modi`s visit of USA become highflier and what make SUN/RBaxy combo approvals as forerunners as SUN is based

4.53 PM Jul 8th 2014

Market Statistician

Platinum Member

12295 Followers

Mangalam Drugs  

Mangalam Drugs & Organics has touched a 52-week high of Rs 10.25. At 15:13 hrs, the share was quoting at Rs 10.19, up Rs 0.27, or 2.72%. See more

3.15 PM Jul 8th 2014

Market Statistician

Platinum Member

12295 Followers

Aarey Drugs  

At 15:13 hrs, Aarey Drugs and Pharmaceuticals was trading at Rs 21.40 up 7.65%, with a huge increase in its volume of shares traded. Till now over 367,096 shares were traded as compared to its 5-day average of 114,854 shares.

3.15 PM Jul 8th 2014

Market Statistician

Platinum Member

12295 Followers

Parenteral Drug  

At 15:14 hrs, Parenteral Drugs (India) was trading at Rs 33.80 up 4.32%, with a huge increase in its volume of shares traded. Till now over 448,621 shares were traded as compared to its 5-day average of 90,823 shares.

3.15 PM Jul 8th 2014

Market Statistician

Platinum Member

12295 Followers

Mangalam Drugs  

Mangalam Drugs & Organics has touched a 52-week high of Rs 10.21. At 14:14 hrs, the share was quoting at Rs 10.25, up Rs 0.33, or 3.33%. See more

2.15 PM Jul 8th 2014

Market Statistician

Platinum Member

12295 Followers

Aarey Drugs  

At 14:12 hrs, Aarey Drugs and Pharmaceuticals was trading at Rs 20.94 up 5.33%, with a huge increase in its volume of shares traded. Till now over 304,764 shares were traded as compared to its 5-day average of 114,854 shares.

2.15 PM Jul 8th 2014

Market Statistician

Platinum Member

12295 Followers

Parenteral Drug  

At 14:13 hrs, Parenteral Drugs (India) was trading at Rs 35.20 up 8.64%, with a huge increase in its volume of shares traded. Till now over 392,958 shares were traded as compared to its 5-day average of 90,823 shares.

2.15 PM Jul 8th 2014

madrasan

Silver Member

1 Followers

Shasun Pharma  

The company might be a beneficiary of the Sevelamer molecule drugs going off patent in the US. Shasun is expected to be one of the Active Pharmaceutical Ingredients (API) supplier of these drugs. The latest indication of these drugs going off patent is that one of the molecules Sevelamer Carbonate

12.48 PM Jul 8th 2014

Market Statistician

Platinum Member

12295 Followers

Aarey Drugs  

At 12:14 hrs, Aarey Drugs and Pharmaceuticals was trading at Rs 20.83 up 4.78%, with a huge increase in its volume of shares traded. Till now over 256,745 shares were traded as compared to its 5-day average of 114,854 shares.

12.15 PM Jul 8th 2014

Market Statistician

Platinum Member

12295 Followers

Parenteral Drug  

At 12:14 hrs, Parenteral Drugs (India) was trading at Rs 36.50 up 12.65%, with a huge increase in its volume of shares traded. Till now over 275,045 shares were traded as compared to its 5-day average of 90,823 shares.

12.15 PM Jul 8th 2014

News across the web »
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.